Abstract
Several authors have hypothesized that antipsychotics could down-regulate the activation of dopamine receptors in the mesolimbic pathway, thus decreasing the occurrence and the intensity of addiction-related symptoms. We conducted a critical review of the theoretical arguments that have been published on this subject and evaluated how they compare to the published clinical data. Despite interesting findings, the effects of antipsychotics may not be as compelling as what would be theoretically expected. Thus far, antipsychotics have shown no efficacy in treating addictive disorders alone. Nevertheless, effective strategies for the use of antipsychotics against addictions are available and discussed. To treat individual vulnerability factors to addictions, such as psychiatric comorbidities (schizophrenia or bipolar disorder) that share vulnerability factors with addictive disorders and contribute to triggering addictive behaviors are among the strategies. The evidence for using antipsychotics is still the best in subjects with comorbid schizophrenia and alcohol or substance use disorder. Additionally, in some clinical situations of major impulsivity, the off-label prescription of atypical antipsychotics is worth exploring, but should be further investigated in a clinical setting.
Keywords: Antipsychotics, addiction, comorbidity, impulsivity, reward system, substance use disorder.
Current Psychopharmacology
Title:Antipsychotics Management in Addictive Disorders
Volume: 2
Author(s): Pierre Alexis Geoffroy, Benjamin Rolland, Vincent Laprevote and Olivier Cottencin
Affiliation:
Keywords: Antipsychotics, addiction, comorbidity, impulsivity, reward system, substance use disorder.
Abstract: Several authors have hypothesized that antipsychotics could down-regulate the activation of dopamine receptors in the mesolimbic pathway, thus decreasing the occurrence and the intensity of addiction-related symptoms. We conducted a critical review of the theoretical arguments that have been published on this subject and evaluated how they compare to the published clinical data. Despite interesting findings, the effects of antipsychotics may not be as compelling as what would be theoretically expected. Thus far, antipsychotics have shown no efficacy in treating addictive disorders alone. Nevertheless, effective strategies for the use of antipsychotics against addictions are available and discussed. To treat individual vulnerability factors to addictions, such as psychiatric comorbidities (schizophrenia or bipolar disorder) that share vulnerability factors with addictive disorders and contribute to triggering addictive behaviors are among the strategies. The evidence for using antipsychotics is still the best in subjects with comorbid schizophrenia and alcohol or substance use disorder. Additionally, in some clinical situations of major impulsivity, the off-label prescription of atypical antipsychotics is worth exploring, but should be further investigated in a clinical setting.
Export Options
About this article
Cite this article as:
Geoffroy Alexis Pierre, Rolland Benjamin, Laprevote Vincent and Cottencin Olivier, Antipsychotics Management in Addictive Disorders, Current Psychopharmacology 2013; 2 (3) . https://dx.doi.org/10.2174/221155601130200006
DOI https://dx.doi.org/10.2174/221155601130200006 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Mechanisms of Immune-to-Brain Communication in Inflammation as a Drug Target
Current Drug Targets - Inflammation & Allergy Vitamin D : Autoimmunity and Gender
Current Medicinal Chemistry Cell Based-Gene Delivery Approaches for the Treatment of Spinal Cord Injury and Neurodegenerative Disorders
Current Stem Cell Research & Therapy Subset Selection and Docking of Human P2X7 Inhibitors
Current Computer-Aided Drug Design Tissue Plasminogen Activator (tPA) and Matrix Metalloproteinases in the Pathogenesis of Stroke: Therapeutic Strategies
CNS & Neurological Disorders - Drug Targets The NMDA/D1 Receptor Complex as a New Target in Drug Development
Current Topics in Medicinal Chemistry Construction of an M1GS Ribozyme for Targeted and Rapid mRNA Cleavage; Application on the Ets-2 Oncogene
Medicinal Chemistry Potassium Channels in Peripheral Pain Pathways: Expression, Function and Therapeutic Potential
Current Neuropharmacology The Role of Placental Carbonyl Reducing Enzymes in Biotransformation of Bupropion and 4-methylnitrosamino-1-(3-pyridyl)-1-butanone
Drug Metabolism Letters Editorial [HotTopic: New and Emerging Approaches to Treatment of Schizophrenia (Guest Editors: Gene G. Kinney and P. Jeffrey Conn)]
Current Neuropharmacology Epidural Analgesia in the Post-Anaesthesia Care Unit
Current Drug Targets Effects of Risperidone in Autistic Children and Young Adults: A Systematic Review and Meta-Analysis
Current Neuropharmacology Antibiotic Properties and Applications of Lactoferrin
Current Pharmaceutical Design Increased Susceptibility to Oxidative Death of Lymphocytes from Alzheimer Patients Correlates with Dementia Severity
Current Alzheimer Research Recent Advances in Perioperative Anesthetic Management Update in the Perioperative Support of Patients with Septic Shock and the Effect on Outcomes
Current Pharmaceutical Design Biophysics of Parkinsons Disease: Structure and Aggregation of α- Synuclein
Current Protein & Peptide Science New Therapeutic Strategies for Coeliac Disease: Tissue Transglutaminase as a Target
Current Medicinal Chemistry Orchestrating HIV Neutralization by Secondary Immune Response- Mediated Induction of RF Antibodies
Current Immunology Reviews (Discontinued) Opioid Peptides and Their Glycoconjugates: Structure-Activity Relationships
Current Medicinal Chemistry - Central Nervous System Agents Irbesartan and Hydrochlorothiazide Association in the Treatment of Hypertension
Current Vascular Pharmacology